Asimov, a leader in synthetic biology for therapeutic design and manufacturing, has announced the launch of its fourth-generation CHO Edge System. This advanced system boasts an increased typical titer range of 5-11 g/L across various biologic architectures, enhancing the probability of producing high titer cell lines and optimizing expression.

The new system guarantees a minimum Cell Line Development (CLD) titer of 5 g/L for IgG monoclonal antibodies. If this benchmark is not met, Asimov waives the service fee and all commercial use license fees, though the lead clone is still transferred to the partner.

The 4th generation CHO Edge System updates include new expression vector architectures, improved genetic parts selection, and refined process methodologies. It integrates AI models to predict signal peptide cleavage, RNA splicing, and upstream process optimization, further refining the system’s capabilities.

A suite of AI models incorporated into the system helps in predictive modeling across various biological processes, contributing to more precise and efficient cell line development.

The system uses a GMP-banked CHO-K1 GS knock-out host (or a GS-Fut8 double knockout), a hyperactive transposase, and a library of over 1,000 characterized genetic parts, ensuring reliable generation of stable cell lines with high titer and product quality.

Alec Nielsen, co-founder and CEO of Asimov, said, “Our 4th generation CHO Edge System incorporates learnings from a wide range of molecules and an array of proprietary data-driven AI models. We have upgraded the vector architectures, genetic parts selection, and predictive modeling across multiple biological processes. While we always target titers in excess of 10 g/L in our CLD process, we can now guarantee a minimum of 5 g/L for IgG molecules. By offering a titer guarantee, we aim to set a new standard for cell line development in the industry and redefine the expectations of therapeutic developers.”

‍

Asimov's 4th generation CHO Edge System represents a significant advancement in the field of synthetic biology and therapeutic manufacturing. By combining cutting-edge AI models with robust genetic engineering, Asimov is setting new benchmarks for efficiency, reliability, and quality in cell line development, thereby enhancing the overall capability and flexibility of therapeutic production processes.

‍